A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia

Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatment insensitivity to FLT3 inhibitors, including sora...

Descripción completa

Detalles Bibliográficos
Autores principales: Damnernsawad, Alisa, Bottomly, Daniel, Kurtz, Stephen E., Eide, Christopher A., McWeeney, Shannon K., Tyner, Jeffrey W., Nechiporuk, Tamilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719098/
https://www.ncbi.nlm.nih.gov/pubmed/33375770
http://dx.doi.org/10.3324/haematol.2020.257964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719098/
https://www.ncbi.nlm.nih.gov/pubmed/33375770
http://dx.doi.org/10.3324/haematol.2020.257964

Ejemplares similares